Monday, 31 August 2026European Markets

ABL Diagnostics Stock Falls By 33% In The Last 21 Sessions

Loading stream...

(vianews) - shares of abl diagnostics (cac 40: abld.pa) fell by a staggering 33.33% in 21 sessions from €8.7 to €5.80 at 17:39 est on monday, after five consecutive sessions in a row of losses. cac 40 is jumping 0.1% to €7,491.50, after two consecutive sessions in a row of gains.

about abl diagnostics

abl diagnostics société anonyme does not have significant operations. the company was formerly known as etablissements fauvet girel and changed its name to abl diagnostics société anonyme in april 2022. the company is headquartered in paris, france. abl diagnostics société anonyme is a subsidiary of advanced biological laboratories (abl) s.a.

earnings per share

as for profitability, abl diagnostics has a trailing twelve months eps of €-0.08.

volatility

abl diagnostics's last week, last month's, and last quarter's current intraday variation average was a negative 22.41%, a negative 22.48%, and a positive 15.48%.

abl diagnostics's highest amplitude of average volatility was 22.41% (last week), 22.48% (last month), and 15.48% (last quarter).

more news about abl diagnostics (abld.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com